Biomarker Core

生物标志物核心

• 批准号: 10474591
• 负责人: Lynn Bekris
• 金额: $ 67.28万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10474591
• 关键词: Address; African American population; Alleles; Alzheimer' s Disease; Alzheimer' s disease related dementia; Amyloid beta-42; Biological Assay; Biological Markers; Blood; CCL2 gene; CXCL10 gene; Cataloging; Catalogs; Cerebrospinal Fluid; Clinic; Clinical Data; Collaborations; Collection; Communities; Consultations; DNA; Data; Data Set; Data Storage and Retrieval; Databases; Dementia; Dementia with Lewy Bodies; Diagnosis; Discrimination; Disease; Disease Progression; Ensure; Foundations; Future; Genetic; Genetic Diseases; Genetic Markers; Genotype; Goals; Heterogeneity; Human; Human Resources; Inflammation; Infrastructure; International; Light; Link; Medical Genetics; Medical center; Mentors; Mission; Molecular; Molecular Analysis; Molecular Genetics; Monitor; National Institute on Aging; Neurochip; Neurodegenerative Disorders; Other Genetics; Participant; Pathogenicity; Pathology; Plasma; Population; Population Heterogeneity; Process; Protein Analysis; Research; Research Personnel; Research Project Grants; Saliva; Sampling; Secure; Skin; Specimen; Symptoms; System; TREM2 gene; Time; Training; Translations; Underrepresented Populations; United States Department of Veterans Affairs; Universities; University Hospitals; Urine; alpha synuclein; apolipoprotein E-4; base; biobank; biological heterogeneity; biomarker discovery; chemokine; clinically relevant; cytokine; data exchange; data management; distributed data; education research; genetic analysis; genetic variant; imaging biomarker; improved; innovation; neurofilament; neuropathology; presenilin-1; programs; protein aggregation; protein biomarkers; repository; specific biomarkers; success; tau Proteins; tau-1; translational therapeutics

PROJECT SUMMARY The mission of the Biomarker Core (BC) is to support Alzheimer's disease (AD) and AD-related dementias (AD/ADRD) research projects by collecting, storing, tracking, sharing, and analyzing biospecimens and associated clinical, genetic, and biomarker data. The collected clinical, genetic, and biomarker data on a variety of human biospecimens will contribute to the understanding of AD/ADRD underlying heterogeneity by cataloging the onset, progression, and disease symptoms of participant biospecimens currently stored in the Cleveland Alzheimer's Disease Research Center (CADRC) BC. This information will contribute to improving diagnosis in unique, understudied populations, as well as the population as a whole. Toward this mission, we previously established and integrated biospecimen collection and research collaborations between Case Western Reserve University, Cleveland Clinic, MetroHealth Systems, University Hospitals, and the Louis Stoke Cleveland VA Medical Center. The aims of the BC are to 1) Facilitate research by leveraging and expanding the CADRC BC infrastructure and biospecimens linked with participant clinical data in the integrated database and continue to include longitudinal biospecimen collection, 2) Provide basic biomarker characterization to facilitate AD/ADRD research, 3) Provide basic genetic characterization to facilitate AD/ADRD research, and 4) Distribute biospecimens to neurodegenerative disease consortiums and coordinating centers, as well as to internal and external investigators. Toward these aims, our team of experts will continue to contribute to biospecimen collection for the CADRC. The establishment of the CADRC BC has provided an essential infrastructure to facilitate and integrate the independent projects of unique and understudied populations, such as African Americans, as well as understudied neurodegenerative disorders, including atypical AD and dementia with Lewy bodies. Standard clinical data (the Uniform Data Set) from these diverse understudied populations will continue to be linked with generated biomarker and genetic data. Genetic and biomarker data linked to relevant clinical data in accordance with goals of the National Alzheimer's Project Act (NAPA) are shared with the scientific community including the Alzheimer's Disease Genetic Consortium (ADGC), National Alzheimer's Coordinating Center (NACC), and the National Institute on Aging Genetics of Alzheimer's Disease Data Storage (NIAGADS). The already established CCLRCBH-Biobank and our highly trained personnel has insured seamless creation of the CADRC BC. Importantly, the CADRC BC infrastructure is now in place to facilitate future innovative AD/ADRD research projects that enhances our understanding of the heterogeneity of AD/ADRD pathology.

项目摘要 生物标志物核心（BC）的任务是支持阿尔茨海默氏病（AD）和与AD相关的痴呆症 （AD/ADRD）研究项目通过收集，存储，跟踪，共享和分析生物测量和分析 相关的临床，遗传和生物标志物数据。收集的临床，遗传和生物标志物数据 人类的生物种类种类将有助于理解AD/ADRD的基本异质性 分类目前存储在参与者生物测量的发作，进展和疾病症状 克利夫兰阿尔茨海默氏病研究中心（CADRC）BC。此信息将有助于改善 在独特的，研究的人群以及整个人群中进行诊断。走向这个任务，我们 以前建立和集成的生物循环收集和研究合作 西部储备大学，克利夫兰诊所，Metrohealth Systems，University Hospitals和Louis Stoke 克利夫兰弗吉尼亚州医疗中心。卑诗省的目的是1）通过利用和扩展来促进研究 CADRC BC基础架构和生物测量与集成数据库中的参与者临床数据相关联 并继续包括纵向生物循环收集，2）提供基本的生物标志物表征 促进AD/ADRD研究，3）提供基本的遗传特征以促进AD/ADRD研究，4） 将生物测量分配给神经退行性疾病联盟和协调中心，以及 内部和外部调查人员。达到这些目标，我们的专家团队将继续为 CADRC的生物循环收集。 CADRC BC的建立提供了必不可少的 促进和整合独特和研究人群的独立项目的基础设施，例如 作为非洲裔美国人，以及正在研究的神经退行性疾病，包括非典型广告和 痴呆症有刘易的身体。来自这些多样的研究的标准临床数据（统一数据集） 种群将继续与生成的生物标志物和遗传数据联系在一起。遗传和生物标志物数据 根据《国家阿尔茨海默氏症计划法》（NAPA）的目标，与相关的临床数据相关联 与科学界分享了包括阿尔茨海默氏病遗传联盟（ADGC），国家 阿尔茨海默氏症协调中心（NACC）和美国国家衰老遗传学研究所 数据存储（Niagads）。已经建立的CCLRCBH-Biobank和我们训练有素的人员有 Cadrc BC的无缝创建。重要的是，CADRC BC基础设施现已到位 促进未来的创新广告/ADRD研究项目，以增强我们对异质性的理解 AD/ADRD病理学。